These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 36544675)

  • 1. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
    Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
    Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value and immunological characteristics of a novel cuproptosis-related long noncoding RNAs risk signature in kidney renal clear cell carcinoma.
    Hong P; Huang W; Du H; Hu D; Cao Q; Wang Y; Zhang H; Tong S; Li Z; Tong M
    Front Genet; 2022; 13():1009555. PubMed ID: 36406128
    [No Abstract]   [Full Text] [Related]  

  • 4. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
    Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
    Front Genet; 2023; 14():1039813. PubMed ID: 36755568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma.
    Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL
    Front Oncol; 2023; 13():1153353. PubMed ID: 37056336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
    Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
    Front Oncol; 2022; 12():966920. PubMed ID: 36276132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
    Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
    Front Oncol; 2022; 12():988680. PubMed ID: 36203428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
    Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
    Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
    Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
    Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
    Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
    Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
    Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
    Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Front Oncol; 2021; 11():663263. PubMed ID: 34123820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
    Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
    World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
    Xu C; Chen A; Mao C; Cui B
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.
    Bai X; Lu F; Li S; Zhao Z; Wang N; Zhao Y; Ma G; Zhang F; Su X; Wang D; Ye J; Li P; Ji C
    Sci Rep; 2024 Jun; 14(1):12926. PubMed ID: 38839842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.